Subtype
Thyroid Gland Medullary Carcinoma
CI-CAN-00004124MTCExplore in graph →
25 active trials3 approved drugs18 evidence items
Loading cancer entity…
Subtype
CI-CAN-00004124MTCExplore in graph →
Clinical trials
105 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) | completed | Phase 1 / Phase 2 | 590 | Hoffmann-La RocheINDUSTRY | 13 | May 31, 2025 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 |
| clinicaltrials |
| NCT01709435 | Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 2 | Dec 22, 2023 | clinicaltrials |
| NCT01730638 | ImmunoTEP for Patients With Medullary Thyroid Carcinoma.(iTEP-CMT) | completed | Phase 1 / Phase 2 | 25 | Nantes University HospitalOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT00514046 | Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2020 | clinicaltrials |
| NCT03246659 | Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC(GRAN-T-MTC) | completed | Phase 1 | 16 | Paola Anna ErbaOTHER | 5 | Mar 20, 2020 | clinicaltrials |
| NCT01539655 | Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib(Vandetanib) | completed | Phase 1 | 34 | SanofiINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT01204476 | Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00028496 | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
Data updated 23 days agoSource updated May 31, 2025source: clinicaltrials